Parabilis Medicines’ (NASDAQ: PBLS) Wall Street debut just reset the bar for biotech IPOs, with the cancer‑focused peptide company raising 670 million dollars in an…
Parabilis Medicines’ (NASDAQ: PBLS) Wall Street debut just reset the bar for biotech IPOs, with the cancer‑focused peptide company raising 670 million dollars in an…